KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology

On August 14, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the NIH’s “Prospective Grant of an Exclusive Patent License: Allogeneic Therapy Using Chimeric Antigen Receptors Targeting GPC3” (85 FR 45912). The… Continue Reading

Italy undertakes bold measures on transparency by adopting the Pricing and Reimbursement Decree

On Friday, 24 July 2020, Italy officially published the long-anticipated Pricing and Reimbursement Decree in the Gazzetta Ufficiale della Repubblica Italiana setting in motion Italy’s place as the first country to implement the WHO transparency resolution (WHA72.8). In statement before… Continue Reading

WTO TRIPS Council (July 2020): The European Union’s position on the interface of IP and health technologies in the COVID-19 response

On 30 July 2020, the World Trade Organization (WTO) convened a formal meeting of the TRIPS Council. The TRIPS Council held discussions on two COVID-19 related topics: agenda item 3 on IP Measures in the Context of COVID-19 and agenda… Continue Reading

KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies

On July 27, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of Exclusive Patent Commercialization License: N6, a Novel, Broad, Highly Potent HIV-Specific Antibody and a Broadly Neutralizing Human Anti-HIV… Continue Reading

WTO TRIPS Council (July 2020): South Africa’s submission on IP and the Public Interest – Beyond Access to Medicines and Medical Technologies towards a more Holistic Approach to TRIPS Flexibilities

On Friday, 17 July 2020, South Africa submitted a paper to the World Trade Organization (WTO) TRIPS Council entitled, Intellectual Property and the Public Interest: Beyond Access to Medicines and Medical Technologies Towards a More Holistic Approach To TRIPS Flexibilities.… Continue Reading

KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment

On July 7, 2020, Knowledge Ecology International (KEI) submitted comments to the Federal Register notice for the National Institutes of Health’s (NIH) “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fenoterol and Certain Fenoterol Analogues for the… Continue Reading

Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

(Update: The NIH provided a response to our comments on July 16, 2020) On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license… Continue Reading